Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Other financing activities (2020 - 2025)

Sanara MedTech (SMTI) has disclosed Other financing activities for 8 consecutive years, with -$3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other financing activities fell 241.78% year-over-year to -$3.5 million, compared with a TTM value of $2.5 million through Sep 2025, down 48.1%, and an annual FY2024 reading of $4.4 million, up 28.85% over the prior year.
  • Other financing activities was -$3.5 million for Q3 2025 at Sanara MedTech, down from $1.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at $3.9 million in Q4 2022 and bottomed at -$3.5 million in Q3 2025.
  • Average Other financing activities over 5 years is $964788.6, with a median of $803386.0 recorded in 2024.
  • The sharpest move saw Other financing activities skyrocketed 434.5% in 2022, then plummeted 241.78% in 2025.
  • Year by year, Other financing activities stood at $728482.0 in 2021, then surged by 434.5% to $3.9 million in 2022, then dropped by 7.72% to $3.6 million in 2023, then dropped by 9.64% to $3.2 million in 2024, then plummeted by 207.95% to -$3.5 million in 2025.
  • Business Quant data shows Other financing activities for SMTI at -$3.5 million in Q3 2025, $1.4 million in Q2 2025, and $1.3 million in Q1 2025.